Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in El Salvador has been developing at a steady pace in recent years.
Customer preferences: El Salvador's population has been increasing steadily, leading to a higher demand for healthcare services and pharmaceutical products. The country's healthcare system is largely public, with private healthcare providers catering to a small segment of the population. The majority of customers prefer generic medicines due to their lower cost, which has led to a rise in the production and sale of generic drugs in the country.
Trends in the market: The Pharmaceuticals market in El Salvador has been growing due to the increasing demand for medicines and healthcare services. The market has been expanding due to the introduction of new drugs and treatments, particularly for chronic diseases such as diabetes and hypertension. The rising incidence of non-communicable diseases has also contributed to the growth of the market. Additionally, the increasing availability of over-the-counter medicines has made healthcare more accessible to the general population.
Local special circumstances: El Salvador has a high prevalence of chronic diseases such as diabetes and hypertension, which has led to a higher demand for pharmaceutical products. The country also has a high incidence of infectious diseases such as dengue fever, which has led to a demand for vaccines and other preventive medicines. The government has implemented various initiatives to improve access to healthcare services and medicines, particularly for low-income families.
Underlying macroeconomic factors: El Salvador's economy has been growing steadily in recent years, which has led to an increase in healthcare spending. The government has been investing in healthcare infrastructure and improving access to healthcare services, which has contributed to the growth of the Pharmaceuticals market. The country's geographic location and trade agreements with other countries have also made it an attractive market for pharmaceutical companies. However, the market is highly regulated, and companies must comply with strict regulations and quality standards to operate in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)